SGLT2 inhibitors: their potential reduction in blood pressure
- 1 January 2015
- journal article
- review article
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 9 (1) , 48-53
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)Current Medical Research and Opinion, 2014
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitorsJournal of the American Society of Hypertension, 2014
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysisJournal of the American Society of Hypertension, 2014
- Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D)Canadian Journal of Diabetes, 2013
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 DiabetesAnnals of Internal Medicine, 2013
- Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysisEuropean Heart Journal, 2010
- Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ, 2003
- Selected major risk factors and global and regional burden of diseaseThe Lancet, 2002
- Diabetes, Hypertension, and Cardiovascular DiseaseHypertension, 2001
- Treatment of Vulvovaginal Candidiasis in Patients With DiabetesDiabetes Care, 1998